Stockreport

Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia

CSL LTD SP/ADR  (CSLLY) 
NASDAQ:AMEX Investor Relations: csl.com/investors
PDF Veltassa® offers effective and well-tolerated long-term potassium control in chronic kidney disease and chronic heart failure patients 1-5Zeria Pharmaceutical Co., Ltd. [Read more]